Clinicians' preferences and attitudes towards the use of lithium in the maintenance treatment of bipolar disorders around the world: a survey from the ISBD Lithium task force.
Diego Hidalgo-Mazzei, Tim Mantingh, Xavier Pérez de Mendiola, Ludovic Samalin, Juan Undurraga, Sergio Strejilevich, Emanuel Severus, Michael Bauer, Ana González-Pinto, Willem A Nolen, Allan H Young, Eduard Vieta
{"title":"Clinicians' preferences and attitudes towards the use of lithium in the maintenance treatment of bipolar disorders around the world: a survey from the ISBD Lithium task force.","authors":"Diego Hidalgo-Mazzei, Tim Mantingh, Xavier Pérez de Mendiola, Ludovic Samalin, Juan Undurraga, Sergio Strejilevich, Emanuel Severus, Michael Bauer, Ana González-Pinto, Willem A Nolen, Allan H Young, Eduard Vieta","doi":"10.1186/s40345-023-00301-y","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Lithium has long been considered the gold-standard pharmacological treatment for the maintenance treatment of bipolar disorders (BD) which is supported by a wide body of evidence. Prior research has shown a steady decline in lithium prescriptions during the last two decades. We aim to identify potential factors explaining this decline across the world with an anonymous worldwide survey developed by the International Society for Bipolar Disorders (ISBD) Task Force \"Role of Lithium in Bipolar Disorders\" and distributed by diverse academic and professional international channels.</p><p><strong>Results: </strong>A total of 886 responses were received of which 606 completed the entire questionnaire while 206 completed it partially. Respondents were from 43 different countries comprising all continents. Lithium was the most preferred treatment option for the maintenance of BD patients (59%). The most relevant clinical circumstances in which lithium was the preferred option were in patients with BD I (53%), a family history of response (18%), and a prior response during acute treatment (17%). In contrast, Lithium was not the preferred option in case of patients´ negative beliefs and/or attitudes towards lithium (13%), acute side-effects or tolerability problems (10%) and intoxication risk (8%). Clinicians were less likely to prefer lithium as a first option in BD maintenance phase when practising in developing economy countries [X2 (1, N = 430) = 9465, p = 0.002) ] and private sectors [X2 (1, N = 434) = 8191, p = 0.004)].</p><p><strong>Conclusions: </strong>Clinicians' preferences and attitudes towards the use of lithium in the maintenance treatment of bipolar disorders appear to be affected by both the patients' beliefs and the professional contexts where clinicians provide their services. More research involving patients is needed for identifying their attitudes toward lithium and factors affecting its use, particularly in developing economies.</p>","PeriodicalId":13944,"journal":{"name":"International Journal of Bipolar Disorders","volume":"11 1","pages":"20"},"PeriodicalIF":2.8000,"publicationDate":"2023-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10220344/pdf/","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Bipolar Disorders","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s40345-023-00301-y","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PSYCHIATRY","Score":null,"Total":0}
引用次数: 3
Abstract
Background: Lithium has long been considered the gold-standard pharmacological treatment for the maintenance treatment of bipolar disorders (BD) which is supported by a wide body of evidence. Prior research has shown a steady decline in lithium prescriptions during the last two decades. We aim to identify potential factors explaining this decline across the world with an anonymous worldwide survey developed by the International Society for Bipolar Disorders (ISBD) Task Force "Role of Lithium in Bipolar Disorders" and distributed by diverse academic and professional international channels.
Results: A total of 886 responses were received of which 606 completed the entire questionnaire while 206 completed it partially. Respondents were from 43 different countries comprising all continents. Lithium was the most preferred treatment option for the maintenance of BD patients (59%). The most relevant clinical circumstances in which lithium was the preferred option were in patients with BD I (53%), a family history of response (18%), and a prior response during acute treatment (17%). In contrast, Lithium was not the preferred option in case of patients´ negative beliefs and/or attitudes towards lithium (13%), acute side-effects or tolerability problems (10%) and intoxication risk (8%). Clinicians were less likely to prefer lithium as a first option in BD maintenance phase when practising in developing economy countries [X2 (1, N = 430) = 9465, p = 0.002) ] and private sectors [X2 (1, N = 434) = 8191, p = 0.004)].
Conclusions: Clinicians' preferences and attitudes towards the use of lithium in the maintenance treatment of bipolar disorders appear to be affected by both the patients' beliefs and the professional contexts where clinicians provide their services. More research involving patients is needed for identifying their attitudes toward lithium and factors affecting its use, particularly in developing economies.
背景:长期以来,锂一直被认为是双相情感障碍(BD)维持治疗的金标准药物治疗,这得到了广泛证据的支持。先前的研究表明,在过去的二十年里,锂的处方在稳步下降。我们的目标是通过国际双相情感障碍协会(ISBD)特别工作组“锂在双相情感障碍中的作用”开展的一项匿名全球调查,确定解释全球范围内这种下降的潜在因素,并通过各种学术和专业国际渠道分发。结果:共收到问卷886份,其中完整填写问卷606份,部分填写问卷206份。受访者来自各大洲的43个不同国家。锂是BD患者最首选的治疗方案(59%)。与首选锂盐治疗最相关的临床情况是:BD I患者(53%)、有反应家族史(18%)和急性治疗期间有反应(17%)。相比之下,在患者对锂的负面信念和/或态度(13%),急性副作用或耐受性问题(10%)和中毒风险(8%)的情况下,锂不是首选。在发展中国家[X2 (1, N = 430) = 9465, p = 0.002]和私营部门[X2 (1, N = 434) = 8191, p = 0.004]执业时,临床医生不太可能选择锂作为BD维持阶段的第一选择。结论:临床医生对在双相情感障碍维持治疗中使用锂的偏好和态度似乎受到患者信念和临床医生提供服务的专业背景的影响。需要对患者进行更多的研究,以确定他们对锂的态度以及影响其使用的因素,特别是在发展中经济体。
期刊介绍:
The International Journal of Bipolar Disorders is a peer-reviewed, open access online journal published under the SpringerOpen brand. It publishes contributions from the broad range of clinical, psychological and biological research in bipolar disorders. It is the official journal of the ECNP-ENBREC (European Network of Bipolar Research Expert Centres ) Bipolar Disorders Network, the International Group for the study of Lithium Treated Patients (IGSLi) and the Deutsche Gesellschaft für Bipolare Störungen (DGBS) and invites clinicians and researchers from around the globe to submit original research papers, short research communications, reviews, guidelines, case reports and letters to the editor that help to enhance understanding of bipolar disorders.